Curriculum Vitae

DR. OOI PO LIN

Medical Lecturer
  • Department of Oncology Clinical
    Faculty of Medicine
  • ooipl

BIOGRAPHY

Dr. Ooi Po Lin is a Clinical Oncologist at the University of Malaya Medical Centre (UMMC) and Faculty of Medicine, University of Malaya. She graduated with a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Malaya in 2015 and obtained her Master of Clinical Oncology in 2024, achieving distinction in core sciences.

Her clinical and research interests focus on breast, gastrointestinal, and urological malignancies, with expertise in chemotherapy, radiotherapy, brachytherapy, and palliative care. Dr. Ooi has contributed to multiple international clinical trials, including PACIFIC-8, ARC-10, DESTINY-LUNG03, and KEYNOTE-B49, and co-authored publications in Annals of Oncology, Annals of General Psychiatry, and Frontiers in Psychology.

Actively engaged in academic and professional development, she serves on organizing committees and as moderator for oncology education programs such as the Masterclass in Systemic Therapy, HCC Masterclass, and Navigator Masterclass. Beyond her clinical and academic commitments, she participates in community and faith-based initiatives, including volunteer teaching in Sunday School.

Outside of work, Dr. Ooi enjoys staying active through Pilates and pickleball, and is currently learning Japanese as part of her personal growth and cross-cultural interests.

ACADEMIC QUALIFICATION

  • MMed (Clinical Oncology), (Onkology Clinical)
    Universiti Malaya (um)
  • MBBS, (Medicine and Surgery)
    Universiti Malaya (um)

ADMINISTRATIVE DUTIES

  • Task Force Leader
    03 Nov 2025 - 31 Dec 2027 (Department)

RESEARCH PROJECT

Private
  1. 2024 - 2028, MERCK SHARP & DOHME (M) SDN. BHD.
    A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 VERSUS TREATMENT OF PHYSICIAN S CHOICE IN 3L+ ADVANCED/METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA (GASTRIC ADENOCARCINOMA, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, AND ESOPHAGEAL ADENOCARCINOMA) ( Principal Investigator(PI))
  2. 2025 - 2027, HEXAL AG, GERMANY
    A RANDOMIZED , DOUBLE-BLIND, PARALLEL-GROUP STUDY TO COMPARE PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY OF JPB898 (PROPOSED NIVOLUMAB BIOSIMILAR) AND US LICENSED AND EU-AUTHORIZED OPTIVO IN COMBINATION WITH YERVOY IN PARTICIPANTS WITH UNTREATED ADVANCED (UNRESECTABLE/METASTATIC) MELANOMA ( Principal Investigator(PI))
  3. 2024 - 2027, BEIGENE MALAYSIA SDN. BHD
    AN OPEN-LABEL, MULTICENTER, LONG-TERM EXTENSION STUDY OF TREATMENT WITH TISLELIZUMAB, PAMIPARIB, AND OTHER INVESTIGATIONAL AGENTS IN PATIENTS WITH ADVANCED MALIGNANCIES ( Co-Researcher)
  4. 2024 - 2027, BEIGENE MALAYSIA SDN. BHD
    AN OPEN-LABEL, MULTICENTER, LONG-TERM EXTENSION STUDY OF TREATMENT WITH TISLELIZUMAB, PAMIPARIB, AND OTHER INVESTIGATIONAL AGENTS IN PATIENTS WITH ADVANCED MALIGNANCIES ( Principal Investigator(PI))
  5. 2024 - 2025, HEXAL AG, GERMANY
    A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO COMPARE PHARMACOKINETICS OF GME751 (PROPOSED PEMBROLIZUMAB BIOSIMILAR) AND US-LICENSED AND EUAUTHORIZED KEYTRUDA IN PARTICIPANTS WITH STAGE II AND III MELANOMA REQUIRING ADJUVANT TREATMENT WITH PEMBROLIZUMAB ( Principal Investigator(PI))
  6. 2025 - 2025, ASTRAZENECA SDN. BHD.
    A PHASE I, MULTICENTER, OPEN-LABEL, FIRST-IN HUMAN, DOSE ESCALATION AND EXPANSION STUDY OF AZD9592 AS MONOTHERAPY AND IN COMBINATION WITH ANTI-CANCER AGENTS IN PATIENTS WITH ADVANCED SOLID TUMORS ( Principal Investigator(PI))

ACADEMIC/ PROF. SERVICES

Mentoring
  1. (2025) Academic Advisor for Masters of Clinical Oncology, University, (Academic Advisor)